Pubblicazioni scientifiche

Di Nunno V.; Mollica V.; Massari F., N-Myc a key gene promoting a worst prostate cancer progression, «TRANSLATIONAL CANCER RESEARCH», 2019, 8, pp. 15 - 17 [Articolo in rivista]

Massari F.; Di Nunno V.; Santoni M.; Gatto L.; Caserta C.; Morelli F.; Zafarana E.; Carrozza F.; Mosca A.; Mollica V.; Iacovelli R.; Sabbatini R.; Porta C.; Bracarda S., Toward a genome-based treatment landscape for renal cell carcinoma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2019, 142, pp. 141 - 152 [Articolo in rivista]

Saeed O.; Lopez-Beltran A.; Fisher K.W.; Scarpelli M.; Montironi R.; Cimadamore A.; Massari F.; Santoni M.; Cheng L., RAS genes in colorectal carcinoma: Pathogenesis, testing guidelines and treatment implications, «JOURNAL OF CLINICAL PATHOLOGY», 2019, 72, pp. 135 - 139 [Articolo in rivista]

Di Nunno V.; Santoni M.; Massari F., New Hormonal Agents in Patients with Nonmetastatic Castration-resistant Prostate Cancer: Can We Be Satisfied with an Advantage in Metastasis-free Survival?, «EUROPEAN UROLOGY ONCOLOGY», 2019, 2, pp. 471 - 471 [Articolo in rivista]

Mollica V.; Di Nunno V.; Gatto L.; Santoni M.; Scarpelli M.; Cimadamore A.; Lopez-Beltran A.; Cheng L.; Battelli N.; Montironi R.; Massari F., Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor, «CANCERS», 2019, 11, pp. 1 - 16 [Articolo in rivista] Open Access

Massari F.; Di Nunno V.; Santoni M.; Gatto L.; Mollica V.; Porta C., Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the End, «EUROPEAN UROLOGY ONCOLOGY», 2019, 2, pp. 603 - 604 [Articolo in rivista]

Gasparrini S.; Cimadamore A.; Scarpelli M.; Massari F.; Doria A.; Mazzucchelli R.; Cheng L.; Lopez-Beltran A.; Montironi R., Contemporary grading of prostate cancer: 2017 update for pathologists and clinicians, «ASIAN JOURNAL OF ANDROLOGY», 2019, 21, pp. 19 - 23 [Articolo in rivista] Open Access

Cimadamore A.; Gasparrini S.; Massari F.; Santoni M.; Cheng L.; Lopez-Beltran A.; Scarpelli M.; Montironi R., Emerging molecular technologies in renal cell carcinoma: Liquid biopsy, «CANCERS», 2019, 11, pp. 1 - 9 [Articolo in rivista] Open Access

Nunno V.D.; Mollica V.; Gatto L.; Santoni M.; Cosmai L.; Porta C.; Massari F., Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: A systematic review and meta-analysis, «IMMUNOTHERAPY», 2019, 11, pp. 631 - 643 [Articolo in rivista]

Prisciandaro M.; Ratta R.; Massari F., Erratum: Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: Real-world data from an Italian managed access program (American Journal of Clinical Oncology: Cancer Clinical Trials (2019) 42 (42-45) DOI: 10.1097/COC.0000000000000478), «AMERICAN JOURNAL OF CLINICAL ONCOLOGY: CANCER CLINICAL TRIALS», 2019, 42, pp. 412 - 412 [Articolo in rivista]

Massari F.; Nunno V.D.; Mollica V.; Montironi R.; Cheng L.; Cimadamore A.; Blanca A.; Lopez-Beltran A., Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice, «IMMUNOTHERAPY», 2019, 11, pp. 1507 - 1521 [Articolo in rivista]

Santoni M.; Cimadamore A.; Cheng L.; Lopez-Beltran A.; Battelli N.; Massari F.; Scarpelli M.; Galosi A.B.; Bracarda S.; Montironi R., Circulating tumor cells in renal cell carcinoma: Recent findings and future challenges, «FRONTIERS IN ONCOLOGY», 2019, 9, pp. 1 - 6 [Articolo in rivista] Open Access

Mollica V.; Di Nunno V.; Cimadamore A.; Lopez-Beltran A.; Cheng L.; Santoni M.; Scarpelli M.; Montironi R.; Massari F., Molecular mechanisms related to hormone inhibition resistance in prostate cancer, «CELLS», 2019, 8, pp. 1 - 15 [Articolo in rivista] Open Access

Iacovelli R.; Galli L.; De Giorgi U.; Porta C.; Nole F.; Zucali P.; Sabbatini R.; Mosca A.; Atzori F.; Santini D.; Facchini G.; Fornarini G.; Buti S.; Massari F.; Masini C.; Ricotta R.; Biasco E.; Lolli C.; Gri N.; Verri E.; Miggiano C.; Vitale M.G.; Tortora G., The effect of a treatment delay on outcome in metastatic renal cell carcinoma, «UROLOGIC ONCOLOGY», 2019, 37, pp. 529 - 535 [Articolo in rivista]

Massari F.; Di Nunno V., CheckMate 214 patient-reported outcomes: listening to our patients, «THE LANCET ONCOLOGY», 2019, 20, pp. 179 - 180 [Articolo in rivista]

Mollica V.; Di Nunno V.; Gatto L.; Santoni M.; Cimadamore A.; Cheng L.; Lopez-Beltran A.; Montironi R.; Pisconti S.; Battelli N.; Massari F., Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution, «CLINICAL DRUG INVESTIGATION», 2019, 39, pp. 503 - 519 [Articolo in rivista]

Santoni M.; Montironi R.; Battelli N.; Massari F., Reply to Michael Staehler, Dena Battle, Axel Bex, Hans Hammers, and Daniel George's Letter to the Editor re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842–3: Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with Immunocheckpoint Inhibitors for Renal Cell Carcinoma, «EUROPEAN UROLOGY», 2019, 75, pp. 64 - 66 [Articolo in rivista]

Castagnetti F.; Gugliotta G.; Soverini S.; Baccarani M.; Rosti G., Current treatment approaches in CML., «HEMASPHERE», 2019, 3, pp. 54 - 56 [Articolo in rivista] Open Access

Cruciani S.; Garroni G.; Ventura C.; Danani A.; Necas A.; Maioli M., Stem cells and physical energies: Can we really drive stem cell fate?, «PHYSIOLOGICAL RESEARCH», 2019, 68, pp. S375 - S384 [Articolo in rivista]

Rossella Sgarzani, Sara Tedeschi, Fabio Trapani, Rita Capirossi, mICAELA bATTILANA, lUCA gAIANI, mASSIMO pALMONARI, lUCA nEGOSANTI, Osteomyelitis of the pelvic bones in patients with spinal cord injury: Is magnetic resonance useful for preoperative diagnosis?, «INTEGRATIVE MOLECULAR MEDICINE», 2019, 6, pp. 1 - 4 [Articolo in rivista]